33.21

0.21% 0.07

After Hours: 33.21

Apellis Pharmaceuticals Inc (APLS)

Overview News Price History Option Chain Financials Why APLS Down? Discussions Forecast

Apellis Pharmaceuticals Inc stock is traded at $33.21, with a volume of 3.52M. It is up +0.21% in the last 24 hours and up +20.81% over the past month. Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Previous Close:

$33.14

Open:

$33.16

24h Volume:

3.52M

Relative Volume:

1.10

Market Cap:

$4.13B

Revenue:

$715.22M

Net Income/Loss:

$-250.10M

P/E Ratio:

-6.3257

EPS:

-5.25

Net Cash Flow:

$-205.58M

1W Performance:

+0.06%

1M Performance:

+20.81%

6M Performance:

-16.41%

1Y Performance:

-39.57%

1-Day Range:

$32.89

$34.27

1-Week Range:

$32.71

$35.70

52-Week Range:

$24.34

$73.80

Apellis Pharmaceuticals Inc Stock (APLS) Company Profile

Name

Apellis Pharmaceuticals Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

617-977-5700

Address

100 FIFTH AVENUE, WALTHAM, KY

Employee

702

Twitter

@ApellisPharma

Next Earnings Date

2024-12-05

Latest SEC Filings

APLS's Discussions on Twitter

Compare APLS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
APLS Apellis Pharmaceuticals Inc	33.21	4.13B	715.22M	-250.10M	-205.58M	-2.03
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-17-24	Downgrade	Goldman	Buy → Neutral
Nov-21-24	Initiated	Morgan Stanley	Equal-Weight
Oct-25-24	Initiated	RBC Capital Mkts	Sector Perform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-16-24	Initiated	William Blair	Outperform
May-31-24	Initiated	Piper Sandler	Neutral
Feb-05-24	Upgrade	Jefferies	Hold → Buy
Dec-14-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-09-23	Initiated	Goldman	Buy
Nov-02-23	Initiated	Mizuho	Neutral
Oct-06-23	Upgrade	JP Morgan	Neutral → Overweight
Sep-15-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Aug-29-23	Reiterated	Citigroup	Buy
Aug-03-23	Downgrade	JP Morgan	Overweight → Neutral
Aug-01-23	Downgrade	BofA Securities	Buy → Neutral
Jan-03-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-10-22	Downgrade	Jefferies	Buy → Hold
Jul-19-22	Initiated	H.C. Wainwright	Buy
Jun-17-22	Resumed	Stifel	Buy
Apr-14-22	Downgrade	ROTH Capital	Neutral → Sell
Dec-08-21	Initiated	Wells Fargo	Overweight
Nov-29-21	Downgrade	ROTH Capital	Buy → Neutral
Sep-10-21	Reiterated	BMO Capital Markets	Outperform
Sep-10-21	Reiterated	Credit Suisse	Neutral
Sep-10-21	Reiterated	Needham	Buy
Sep-10-21	Reiterated	Oppenheimer	Outperform
Sep-10-21	Downgrade	Wedbush	Outperform → Neutral
Aug-19-21	Initiated	Jefferies	Buy
Aug-19-21	Upgrade	Wedbush	Neutral → Outperform
May-21-21	Initiated	UBS	Buy
Apr-16-21	Initiated	Goldman	Buy
Nov-19-20	Initiated	Needham	Buy
Sep-01-20	Initiated	Stifel	Buy
Jul-20-20	Initiated	ROTH Capital	Buy
Jun-17-20	Initiated	BTIG Research	Neutral
Apr-01-20	Initiated	Raymond James	Strong Buy
Mar-31-20	Initiated	BMO Capital Markets	Outperform
Mar-11-20	Upgrade	Wedbush	Underperform → Neutral
Jan-07-20	Initiated	SVB Leerink	Mkt Perform
Dec-19-19	Initiated	BofA/Merrill	Buy
Nov-22-19	Initiated	Wedbush	Underperform
Nov-05-19	Initiated	Credit Suisse	Neutral
Aug-01-19	Reiterated	Cantor Fitzgerald	Overweight
Jul-12-19	Upgrade	JP Morgan	Neutral → Overweight
Mar-29-19	Initiated	Robert W. Baird	Outperform
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Jul-30-18	Upgrade	B. Riley FBR	Neutral → Buy
May-24-18	Initiated	Cantor Fitzgerald	Overweight
Apr-12-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
Feb-08-18	Initiated	B. Riley FBR, Inc.	Buy

View All

Apellis Pharmaceuticals Inc Stock (APLS) Latest News

03:31 AM

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

03:31 AM

Dec 19, 2024

Barclays PLC Raises Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat

Dec 19, 2024

Dec 17, 2024

Goldman Sachs Downgrades Apellis Pharmaceuticals (APLS) - MSN

Dec 17, 2024

Apellis Pharmaceuticals (NASDAQ:APLS) Downgraded by The Goldman Sachs Group to "Neutral" - MarketBeat

Dec 17, 2024

Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (20 Ratings) - Benzinga

Dec 17, 2024

This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga

Dec 17, 2024

Mama's Creations Posts Weak Earnings, Joins EVgo, Red Cat Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga

Dec 17, 2024

Dec 16, 2024

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Short Interest Down 5.9% in November - MarketBeat

Dec 16, 2024

State Street Corp Has $116.54 Million Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat

Dec 16, 2024

Dec 15, 2024

There's No Escaping Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Muted Revenues Despite A 26% Share Price Rise - Simply Wall St

Dec 15, 2024

Dec 12, 2024

Should You Hold Apellis Pharmaceuticals (APLS)? - Insider Monkey

Dec 12, 2024

Dec 11, 2024

Old West Investment Management LLC Acquires Shares of 102,403 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat

Dec 11, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 17,119 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat

Dec 11, 2024

Dec 10, 2024

Geographic Atrophy Market: Rapid Growth and Key Research - openPR

Dec 10, 2024

Dec 06, 2024